$AIMD
Ainos, Inc.

2016 Q3 Form 10-Q Financial Statement

#000101476316000037 Filed on August 18, 2016

View on sec.gov

Income Statement

Concept 2016 Q3 2016 Q2 2015 Q2
Revenue
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $178.5K $135.1K $102.1K
YoY Change 57.17% 32.34% -46.26%
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $178.5K $135.1K $102.1K
YoY Change 57.17% 32.34% -46.26%
Operating Profit -$178.5K -$135.1K -$102.1K
YoY Change 57.17% 32.34% -46.26%
Interest Expense $798.00 $1.097K $746.00
YoY Change 33.89% 47.05%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$180.0K -$140.0K -$100.0K
YoY Change 63.64% 40.0% -47.37%
Income Tax
% Of Pretax Income
Net Earnings -$179.3K -$136.2K -$102.8K
YoY Change 57.05% 32.45% -45.87%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$0.13 -$0.10 -$0.08
COMMON SHARES
Basic Shares Outstanding 21.39M
Diluted Shares Outstanding

Balance Sheet

Concept 2016 Q3 2016 Q2 2015 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $180.0K $310.0K $100.0K
YoY Change -18.18% 210.0%
Cash & Equivalents $176.4K $312.3K $100.1K
Short-Term Investments
Other Short-Term Assets $110.0K $140.0K $50.00K
YoY Change 266.67% 180.0% 0.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $281.5K $453.8K $150.0K
YoY Change 12.59% 202.52% 200.0%
LONG-TERM ASSETS
Property, Plant & Equipment $45.87K $50.17K $10.00K
YoY Change 358.69% 401.74%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $160.5K $135.0K $90.00K
YoY Change 78.31% 50.02% 0.0%
TOTAL ASSETS
Total Short-Term Assets $281.5K $453.8K $150.0K
Total Long-Term Assets $160.5K $135.0K $90.00K
Total Assets $442.0K $588.8K $240.0K
YoY Change 29.99% 145.33% 71.43%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $130.0K $100.0K $100.0K
YoY Change -40.91% 0.0% -78.26%
Accrued Expenses $0.00 $0.00 $0.00
YoY Change -100.0%
Deferred Revenue
YoY Change
Short-Term Debt $790.0K $790.0K $270.0K
YoY Change 107.89% 192.59% -92.72%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $929.3K $896.8K $370.0K
YoY Change 52.34% 142.38% -93.03%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $110.0K
YoY Change -100.0%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $110.0K
YoY Change -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $929.3K $896.8K $370.0K
Total Long-Term Liabilities $0.00 $0.00 $110.0K
Total Liabilities $929.3K $896.8K $480.0K
YoY Change 52.34% 86.84% -90.96%
SHAREHOLDERS EQUITY
Retained Earnings -$1.034M -$854.5K
YoY Change
Common Stock $213.9K $213.9K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$487.3K -$308.0K -$250.0K
YoY Change
Total Liabilities & Shareholders Equity $442.0K $588.8K $240.0K
YoY Change 29.99% 145.33% 71.43%

Cashflow Statement

Concept 2016 Q3 2016 Q2 2015 Q2
OPERATING ACTIVITIES
Net Income -$179.3K -$136.2K -$102.8K
YoY Change 57.05% 32.45% -45.87%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$100.0K -$330.0K -$140.0K
YoY Change -183.33% 135.71% 100.0%
INVESTING ACTIVITIES
Capital Expenditures $30.00K $60.00K $0.00
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$30.00K -$60.00K $0.00
YoY Change -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 430.0K 0.000
YoY Change -100.0%
NET CHANGE
Cash From Operating Activities -100.0K -330.0K -140.0K
Cash From Investing Activities -30.00K -60.00K 0.000
Cash From Financing Activities 0.000 430.0K 0.000
Net Change In Cash -130.0K 40.00K -140.0K
YoY Change -208.33% -128.57%
FREE CASH FLOW
Cash From Operating Activities -$100.0K -$330.0K -$140.0K
Capital Expenditures $30.00K $60.00K $0.00
Free Cash Flow -$130.0K -$390.0K -$140.0K
YoY Change -208.33% 178.57% 75.0%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2015 amar Adjustments To Additional Paid In Capital Stock Issuance
AdjustmentsToAdditionalPaidInCapitalStockIssuance
80574
CY2015 amar Adjustments To Additional Paid In Capital Stock Subscription
AdjustmentsToAdditionalPaidInCapitalStockSubscription
80574
CY2016Q1 amar Amount Of Private Placement
AmountOfPrivatePlacement
937500
CY2016Q2 amar Common Stock Shares Outstanding And Reserved
CommonStockSharesOutstandingAndReserved
25714017
CY2015Q4 amar Common Stock Subscribed Purchase Premium
CommonStockSubscribedPurchasePremium
80574
CY2015Q4 amar Common Stock Subscribed Purchase Price
CommonStockSubscribedPurchasePrice
144426
amar Conversion Of Accounts Payable Related Party To Convertible Note Payable Related Party
ConversionOfAccountsPayableRelatedPartyToConvertibleNotePayableRelatedParty
144426
amar Conversion Of Accounts Payable Related Party To Convertible Note Payable Related Party
ConversionOfAccountsPayableRelatedPartyToConvertibleNotePayableRelatedParty
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Voluntary Filers
EntityVoluntaryFilers
No
dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
dei Amendment Flag
AmendmentFlag
false
dei Entity Registrant Name
EntityRegistrantName
AMARILLO BIOSCIENCES INC
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Document Period End Date
DocumentPeriodEndDate
2016-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2016
dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
CY2016Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
21394810
dei Document Type
DocumentType
10-Q
dei Trading Symbol
TradingSymbol
amar
dei Entity Central Index Key
EntityCentralIndexKey
0001014763
amar Conversion Of Notes Payable Related Party To Convertible Note Payable Related Party
ConversionOfNotesPayableRelatedPartyToConvertibleNotePayableRelatedParty
384555
amar Conversion Of Notes Payable Related Party To Convertible Note Payable Related Party
ConversionOfNotesPayableRelatedPartyToConvertibleNotePayableRelatedParty
CY2016Q2 amar Notes Payable Convertible Related Parties Classified Current
NotesPayableConvertibleRelatedPartiesClassifiedCurrent
791481
CY2015Q4 amar Notes Payable Convertible Related Parties Classified Current
NotesPayableConvertibleRelatedPartiesClassifiedCurrent
CY2015Q3 amar Payment Received From Investors As Payment Of A Subscribed Investment
PaymentReceivedFromInvestorsAsPaymentOfASubscribedInvestment
225000
CY2015 amar Payment Received From Investors As Paymnet Of A Subscribed Investment
PaymentReceivedFromInvestorsAsPaymnetOfASubscribedInvestment
225000
CY2015Q3 amar Premium Over The Price Of Stock Price
PremiumOverThePriceOfStockPrice
0.07
CY2016Q2 amar Share Based Compensation Awards Other Than Options Exercisable Number
ShareBasedCompensationAwardsOtherThanOptionsExercisableNumber
CY2016Q2 amar Shares Authorized During Period Private Placement
SharesAuthorizedDuringPeriodPrivatePlacement
2250000
CY2016Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
102809
CY2015Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
58550
CY2016Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
332505
CY2015Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
-76872
CY2016Q2 us-gaap Assets
Assets
588794
CY2015Q4 us-gaap Assets
Assets
117195
CY2016Q2 us-gaap Assets Current
AssetsCurrent
453778
CY2015Q4 us-gaap Assets Current
AssetsCurrent
39292
us-gaap Basis Of Accounting
BasisOfAccounting
<div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px; width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr> <td style="VERTICAL-ALIGN: top; WIDTH: 36pt"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: justify; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">2.</div></div></td> <td style="VERTICAL-ALIGN: top"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: justify; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Basis of presentation. The accompanying financial statements, which should be read in conjunction with the financial statements and footnotes included in the Company's Form 10-K for the year ended December 31, 2015, filed with the Securities and Exchange Commission, are unaudited, but have been prepared in accordance with accounting principles generally accepted in the United States for interim financial information. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States for complete financial statements. In the opinion of management, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation have been included. Operating results for the six months ended June 30, 2016 are not necessarily indicative of the results that may be expected for the full year ending December 31, 2016.</div></div></td> </tr> </table></div>
CY2016Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
312261
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
21138
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
318556
CY2015Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
100064
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
291123
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-218492
CY2016Q2 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
0
CY2016Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2015Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2016Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2015Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2016Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2015Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2016Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
21394810
CY2015Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
20144810
CY2016Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
21394810
CY2015Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
20144810
CY2015Q3 us-gaap Common Stock Shares Subscribed But Unissued
CommonStockSharesSubscribedButUnissued
1200000
CY2015Q4 us-gaap Common Stock Shares Subscribed But Unissued
CommonStockSharesSubscribedButUnissued
1200000
CY2016Q2 us-gaap Common Stock Value
CommonStockValue
213948
CY2015Q4 us-gaap Common Stock Value
CommonStockValue
201448
us-gaap Gross Profit
GrossProfit
-700
us-gaap Gross Profit
GrossProfit
us-gaap Income Taxes Paid
IncomeTaxesPaid
us-gaap Income Taxes Paid
IncomeTaxesPaid
CY2016Q2 us-gaap Interest Expense
InterestExpense
1097
CY2015Q2 us-gaap Interest Expense
InterestExpense
746
CY2016Q2 us-gaap Cost Of Goods Sold
CostOfGoodsSold
CY2015Q2 us-gaap Cost Of Goods Sold
CostOfGoodsSold
us-gaap Cost Of Goods Sold
CostOfGoodsSold
5100
us-gaap Cost Of Goods Sold
CostOfGoodsSold
CY2016Q2 us-gaap Cost Of Revenue
CostOfRevenue
CY2015Q2 us-gaap Cost Of Revenue
CostOfRevenue
us-gaap Cost Of Revenue
CostOfRevenue
5100
us-gaap Cost Of Revenue
CostOfRevenue
CY2016Q2 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
CY2015Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
144426
CY2016Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.01
CY2015Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.01
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.01
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.01
CY2016Q2 us-gaap Finite Lived Patents Gross
FiniteLivedPatentsGross
84842
CY2015Q4 us-gaap Finite Lived Patents Gross
FiniteLivedPatentsGross
72105
CY2016Q2 us-gaap Gross Profit
GrossProfit
CY2015Q2 us-gaap Gross Profit
GrossProfit
us-gaap Interest Expense
InterestExpense
1459
us-gaap Interest Expense
InterestExpense
1017
us-gaap Interest Paid
InterestPaid
us-gaap Interest Paid
InterestPaid
CY2016Q2 us-gaap Liabilities
Liabilities
896824
CY2015Q4 us-gaap Liabilities
Liabilities
589237
CY2016Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
588794
CY2015Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
117195
CY2016Q2 us-gaap Liabilities Current
LiabilitiesCurrent
896824
CY2015Q4 us-gaap Liabilities Current
LiabilitiesCurrent
589237
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
684375
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-68132
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-11066
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-325120
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-207426
CY2016Q2 us-gaap Net Income Loss
NetIncomeLoss
-136224
CY2015Q2 us-gaap Net Income Loss
NetIncomeLoss
-102849
us-gaap Net Income Loss
NetIncomeLoss
-257865
us-gaap Net Income Loss
NetIncomeLoss
-214938
CY2016Q2 us-gaap Notes Payable Related Parties Classified Current
NotesPayableRelatedPartiesClassifiedCurrent
CY2015Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2015Q4 us-gaap Notes Payable Related Parties Classified Current
NotesPayableRelatedPartiesClassifiedCurrent
384555
CY2016Q2 us-gaap Notes Payable Related Parties Current And Noncurrent
NotesPayableRelatedPartiesCurrentAndNoncurrent
CY2015Q4 us-gaap Notes Payable Related Parties Current And Noncurrent
NotesPayableRelatedPartiesCurrentAndNoncurrent
384555
CY2016Q2 us-gaap Notes Payable Related Parties Noncurrent
NotesPayableRelatedPartiesNoncurrent
0
CY2015Q4 us-gaap Notes Payable Related Parties Noncurrent
NotesPayableRelatedPartiesNoncurrent
0
CY2016Q2 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
135127
CY2015Q2 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
102103
us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
255706
us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
213921
CY2016Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-135127
CY2015Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-102103
us-gaap Operating Income Loss
OperatingIncomeLoss
-256406
us-gaap Operating Income Loss
OperatingIncomeLoss
-213921
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
20446
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
3985
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
47686
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
7081
CY2016Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2015Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2016Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2015Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2016Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2015Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2016Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2015Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2016Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2016Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
141517
CY2015Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
18154
CY2016Q2 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
421875
us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
421875
us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
262500
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
CY2016Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
50174
CY2015Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5798
CY2016Q2 us-gaap Related Party Transaction Due From To Related Party Current
RelatedPartyTransactionDueFromToRelatedPartyCurrent
-2534
CY2015Q4 us-gaap Related Party Transaction Due From To Related Party Current
RelatedPartyTransactionDueFromToRelatedPartyCurrent
-1706
CY2015Q4 us-gaap Stockholders Equity
StockholdersEquity
-472042
CY2016Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
CY2015Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
CY2016Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-854483
CY2015Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-596618
CY2016Q2 us-gaap Revenues
Revenues
CY2015Q2 us-gaap Revenues
Revenues
us-gaap Revenues
Revenues
4400
us-gaap Revenues
Revenues
CY2016Q2 us-gaap Sales Revenue Goods Gross
SalesRevenueGoodsGross
CY2015Q2 us-gaap Sales Revenue Goods Gross
SalesRevenueGoodsGross
us-gaap Sales Revenue Goods Gross
SalesRevenueGoodsGross
4400
us-gaap Sales Revenue Goods Gross
SalesRevenueGoodsGross
CY2016Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
135127
CY2015Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
102103
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
255706
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
213921
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
8568
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
0.95
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
8568
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
8568
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.95
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.95
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
CY2015Q3 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
0.12
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
CY2016Q2 us-gaap Stockholders Equity
StockholdersEquity
-308030
CY2016Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
21069535
CY2015Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
20144810
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
20607173
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
20144810

Files In Submission

Name View Source Status
0001014763-16-000037-index-headers.html Edgar Link pending
0001014763-16-000037-index.html Edgar Link pending
0001014763-16-000037.txt Edgar Link pending
0001014763-16-000037-xbrl.zip Edgar Link pending
amar-20160630.xml Edgar Link completed
amar-20160630.xsd Edgar Link pending
amar-20160630_cal.xml Edgar Link unprocessable
amar-20160630_def.xml Edgar Link unprocessable
amar-20160630_lab.xml Edgar Link unprocessable
amar-20160630_pre.xml Edgar Link unprocessable
exhibit31-1a_06302016.htm Edgar Link pending
exhibit31-1b_06302016.htm Edgar Link pending
exhibit32-1_06302016.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
form10q_06302016.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending